Leiomyosarcoma

doi:10.1017/9781108332798.017

Chapter 16 - Leiomyosarcoma

Implications for the Treatment of Fibroids

Published online by Cambridge University Press: 10 October 2020

Elizabeth A. Pritts

Edited by

Mostafa Metwally and

Tin-Chiu Li

Show author details

Mostafa Metwally: Affiliation:
University of Sheffield
Tin-Chiu Li: Affiliation:
The Chinese University of Hong Kong

Book contents

Get access

Summary

The risk of finding an occult leiomyosarcoma (LMS) at surgery for presumed leiomyomas and subsequent outcomes for patients who have these tumours morcellated is a subject of conflict in gynaecology today. This dispute arose in 2013 from a single case in which a physician underwent surgery for fibroids and power morcellation was utilized. This physician ultimately was diagnosed with an LMS and she and her family began a media campaign and created a public forum to effect a ban on power morcellation. They argued that prevalence of these occult tumours was much higher than originally believed, and the use of power morcellation worsened outcomes. Originally, a friend of the physician performed a cursory meta-analysis using incomplete data suggesting that the rate of uterine sarcoma in women having surgery for presumed fibroids was 1 in 323. The US Food and Drug Administration (FDA) used similar but slightly different methodology and found a prevalence of 1 in 352 for uterine sarcoma, and 1 in 498 for leiomyosarcoma [1]. Neither analysis has been published in a peer-reviewed journal, and both represent incomplete and biased attempts at establishing a prevalence rate.

Information

Type: Chapter
Information: Modern Management of Uterine Fibroids , pp. 155 - 164

DOI: https://doi.org/10.1017/9781108332798.017 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

FDA. Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids: summary and key findings, April 17, 2014. www.fda.gov/media/88703/download. Accessed April 2020.Google Scholar

Pritts, EA, Vanness, DJ, Berek, JS, et al. The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecol Surg 2015;12:165–77.CrossRef Google Scholar PubMed

Hartmann, KE, Fonnesbeck, C, Surawicz, T, et al. Management of uterine fibroids. Comparative effectiveness review no. 195 (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2015-00003-I.) AHRQ Publication No. 17(18)-EHC028-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2017. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/cer-195-uterine-fibroids-final-revision.pdf. Accessed April 2020.Google Scholar

Olive, DL. The dangers of junk science in obstetrics and gynecology: lessons from the power morcellation controversy. Curr Opin Obstet Gynecol 2015;27:249–52.Google Scholar

Mettler, L, Alvarez-Rodas, E, Semm, K. Hormonal treatment and pelviscopic myomectomy. Diagn Ther Endosc 1995;1:217–21.Google Scholar

Nagurney, JT, Brown, DF, Sane, S, et al. The accuracy and completeness of data collected by prospective and retrospective methods. Acad Emerg Med 2005 Sept;12(9):884–95.Google Scholar

Harbour, R, Miller, J. A new system for grading recommendations in evidence-based guidelines. Br Med J 2001;323:334–6.Google Scholar

Bradburn, MJ, Deeks, JJ, Berlin, JA, et al. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007;26:53–77.Google Scholar

Altman, DG, Deeks, JJ. Meta-analysis, Simpson’s paradox, and the number needed to treat. BMC Med Res Methodol 2002;26:53–77.Google Scholar

Bell, SW, Kempson, RL, Hendrickson, MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol 1994 Jun;18(6):535–58.Google Scholar

WHO Classification of Tumours. In: Tavassoli, FA, Devilee, P, editors. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003:233–8.Google Scholar

Leibsohn, S, d’Ablaing, G, Mishell, D, et al. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol 1990;162:968–76.Google Scholar

Parker, WH, Fu, YS, Berek, JS. Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma. Obstet Gynecol 1994;83:414–18.Google Scholar PubMed

Seki, K, Hoshihara, T, Nagata, I. Leiomyosarcoma of the uterus: ultrasonography and serum lactate dehydrogenase level. Gynecol Obstet Investig 1992;33:114–18.CrossRef Google Scholar PubMed

Oduyebo, T, Rauh-Hain, AJ, Meserve, EE, et al. The value of re-exploration in patients with inadvertently morcellated uterine sarcoma. Gynecol Oncol 2014 Feb;132(2):360–5. doi: 10.1016/j.ygyno.2013.11.024.Google Scholar

George, S, Varysauskas, C, Serrano, C, et al. Retrospective cohort study evaluating the impact of intraperitoneal morcellation of outcomes of localized uterine leiomyosarcoma. Cancer 2014 Oct 15;120(20):3154–8. doi: 10.1002/cncr.28844.Google Scholar

Seidman, MA, Hinchcliff, E, George, S, et al. PLoS One. 2012;7(11):e50058. doi: 10.1371/journal.pone.0050058.CrossRef Google Scholar

Park, JY, Park, SK, Kim, DY, et al. The impact of tumour morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma. Gynecol Oncol 2011;122:255–9.Google Scholar

Morice, P, Rodriquez, A, Rey, A, et al. Prognostic value of initial surgical procedure for patient with uterine sarcoma: analysis of 123 patients. Eur J Gynaecol Oncol 2003;24:237–40.Google Scholar

Pritts, EA, Parker, WH, Brown, JB, et al. Outcome of occult uterine leiomyosarcoma after surgery for presumed uterine fibroids: a systematic review. J Minim Invasive Gynecol 2015;22:26–33.Google Scholar

Einstein, MH, Barakat, RR, Chi, DS, et al. Management of uterine malignancy found incidentally after supracervical hysterectomy or uterine morcellation for presumed benign disease. Int J Gynecol Cancer 2008;18:1065–70.Google Scholar

Perri, T, Korach, J, Sadetzki, S, et al. Uterine leiomyosarcoma: does the primary surgical procedure matter? Int J Gynecol Cancer 2009;19:257–60.CrossRef Google Scholar PubMed

Accessibility standard: Unknown

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.